RecruitingAtopic Dermatitis
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Sponsor: Brexogen Inc.
You may qualify if…
- ✓ 1. Patients (males or females) aged 18 years or older.
- ✓ 2. Patients have documented history of moderate to severe AD, that has been present for at least 1 year
- ✓ 3. History of inadequate response to a stable regimen of TCSs or TCIs as treatment for AD
- ✓ 4. Patients must agree to apply stable doses of additive-free, basic bland emollient lotions twice daily for at least 7 days before the Baseline Visit.
- ✓ 5. Willingness and ability to comply with clinic visits and study-related procedures.
- ✓ 6. Patients should be able to read, understand, and be willing to sign the ICF
You may not qualify if…
- ✕ 1. Presence of any of the following laboratory abnormalities
- ✕ Hemoglobin \< 11 g/dL
- ✕ WBC \< 3.5 × 103/μL
- ✕ Platelet count \< 125 × 103/μL
- ✕ Neutrophils \< 1.75 × 103/μL
- ✕ AST/ALT \> 1.5 × ULN
- ✕ Total bilirubin \> ULN
- ✕ Creatinine \> ULN
Where it's recruiting
Arkansas
North Little Rock
Pennsylvania
Camp Hill · Philadelphia
Source: ClinicalTrials.gov · NCT06055361 · last updated 2025-09-19